Level of exposure to each product and delay between cycles in the PVAB regimen
| . | Cycle 1 (n = 89) . | Cycle 2 (n = 84) . | Cycle 3 (n = 84) . | Cycle 4 (n = 83) . | Cycle 5 (n = 79) . | Cycle 6 (n = 78) . |
|---|---|---|---|---|---|---|
| Total dose taken | ||||||
| Prednisone (200 mg/m2)∗ | ||||||
| Median dose | 199.0 | 200.4 | 200.3 | 198.6 | 198.5 | 199.7 |
| Min to max | 38-241 | 38-241 | 50-243 | 49-244 | 50-243 | 50-241 |
| PPD (%) | 99.5 | 100.2 | 100.1 | 99.3 | 99.3 | 99.8 |
| Min to max | 19-121 | 19-121 | 25-121 | 24-122 | 25-121 | 25-121 |
| Vinblastine (6 mg/m2)∗ | ||||||
| Median dose | 5.9 | 5.9 | 5.9 | 5.8 | 5.9 | 5.9 |
| Min to max | 5-7 | 5-6 | 5-6 | 5-6 | 3-6 | 3-6 |
| PPD (%) | 98.3 | 98.3 | 97.5 | 96.7 | 98.3 | 98.3 |
| Min to max | 78-110 | 78-107 | 75-105 | 75-103 | 50-105 | 45-105 |
| Doxorubicin (40 mg/m2)∗ | ||||||
| Median dose | 39.8 | 39.9 | 39.9 | 39.5 | 39.6 | 39.6 |
| Min to max | 34-44 | 30-44 | 28-44 | 19-43 | 19-43 | 0-43 |
| PPD (%) | 99.5 | 99.8 | 99.6 | 98.8 | 99.0 | 99.0 |
| Min to max | 85-109 | 75-110 | 70-110 | 47-109 | 47-108 | 0-108 |
| Bendamustine (120 mg/m2)∗ | ||||||
| Median dose | 119.2 | 119.6 | 119.4 | 118.6 | 118.4 | 118.7 |
| Min to max | 102-131 | 89-127 | 85-125 | 56-129 | 56-125 | 56-125 |
| PPD (%) | 99.3 | 99.7 | 99.5 | 98.8 | 98.7 | 98.9 |
| Min to max | 85-109 | 74-106 | 71-104 | 47-108 | 47-105 | 47-104 |
| . | Cycle 1 (n = 89) . | Cycle 2 (n = 84) . | Cycle 3 (n = 84) . | Cycle 4 (n = 83) . | Cycle 5 (n = 79) . | Cycle 6 (n = 78) . |
|---|---|---|---|---|---|---|
| Total dose taken | ||||||
| Prednisone (200 mg/m2)∗ | ||||||
| Median dose | 199.0 | 200.4 | 200.3 | 198.6 | 198.5 | 199.7 |
| Min to max | 38-241 | 38-241 | 50-243 | 49-244 | 50-243 | 50-241 |
| PPD (%) | 99.5 | 100.2 | 100.1 | 99.3 | 99.3 | 99.8 |
| Min to max | 19-121 | 19-121 | 25-121 | 24-122 | 25-121 | 25-121 |
| Vinblastine (6 mg/m2)∗ | ||||||
| Median dose | 5.9 | 5.9 | 5.9 | 5.8 | 5.9 | 5.9 |
| Min to max | 5-7 | 5-6 | 5-6 | 5-6 | 3-6 | 3-6 |
| PPD (%) | 98.3 | 98.3 | 97.5 | 96.7 | 98.3 | 98.3 |
| Min to max | 78-110 | 78-107 | 75-105 | 75-103 | 50-105 | 45-105 |
| Doxorubicin (40 mg/m2)∗ | ||||||
| Median dose | 39.8 | 39.9 | 39.9 | 39.5 | 39.6 | 39.6 |
| Min to max | 34-44 | 30-44 | 28-44 | 19-43 | 19-43 | 0-43 |
| PPD (%) | 99.5 | 99.8 | 99.6 | 98.8 | 99.0 | 99.0 |
| Min to max | 85-109 | 75-110 | 70-110 | 47-109 | 47-108 | 0-108 |
| Bendamustine (120 mg/m2)∗ | ||||||
| Median dose | 119.2 | 119.6 | 119.4 | 118.6 | 118.4 | 118.7 |
| Min to max | 102-131 | 89-127 | 85-125 | 56-129 | 56-125 | 56-125 |
| PPD (%) | 99.3 | 99.7 | 99.5 | 98.8 | 98.7 | 98.9 |
| Min to max | 85-109 | 74-106 | 71-104 | 47-108 | 47-105 | 47-104 |
| Delay between 2 cycles . | C1-C2 . | C2-C3 . | C3-C4 . | C4-C5 . | C5-C6 . |
|---|---|---|---|---|---|
| N | N = 84 | N = 84 | N = 83 | N = 79 | N = 78 |
| Median | 21 | 21 | 21 | 21 | 21 |
| Min to max | 20-28 | 19-36 | 18-56 | 19-31 | 18-35 |
| Delay between 2 cycles . | C1-C2 . | C2-C3 . | C3-C4 . | C4-C5 . | C5-C6 . |
|---|---|---|---|---|---|
| N | N = 84 | N = 84 | N = 83 | N = 79 | N = 78 |
| Median | 21 | 21 | 21 | 21 | 21 |
| Min to max | 20-28 | 19-36 | 18-56 | 19-31 | 18-35 |
C1, cycle 1; max, maximum; min, minimum; PPD, percentage of planned dose.
Expected dose per cycle.